Pharmacokinetics and absolute bioavailability of lansoprazole

European Journal of Clinical Pharmacology

Volumn 50, Issue 4, 1996, Pages 293-297

  Gerloff, J ^a   Mignot, A ^b   Barth, H ^a   Heintze, K ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b CEPHAC Analytical   (France)

Author keywords

Absolute bioavailability; Debrisoquine sparteine phenotype; Lansoprazole; Mephenytoin phenotype; Pharmacokinetics

Indexed keywords

LANSOPRAZOLE; MEPHENYTOIN; SPARTEINE;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OMEPRAZOLE; PHENOTYPE; TABLETS, ENTERIC-COATED;

EID: 0029941128     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050111     Document Type: Article

References (20)

1. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 248:799-805
2. Satoh H, Inatomi N, Nagaya H, et al (1989) Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharm Exp Ther 248:806-815
3. Barradell LB, Faulds D, McTavish D (1992) Lansoprazole, a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 44:225-250
4. Arakawa T, Higuchi K, Fukuda T, Nakumura H, Kobayashi K (1991) H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. J Clin Gastroenterol 13 (Suppl 1): 129-133
5. Andersson T, Andrén K, Cederberg C, Lagerström P-O, Lundborg P, Skånberg I (1990) Pharmacokinetics and bioavailability of omeprazole after single and repeated administration in healthy subjects. Br J Clin Pharmacol 29:557-563
6. Andersson T, Regårdh C-G (1990) Pharmacokinetics of omeprazole and metabolites following single intravenous and oral doses of 40 and 80 mg. Drug Invest 2:255-263
7. Eichelbaum M, Reetz KP, Schmidt EK, Zekorn C (1986) The genetic polymorphism of sparteine metabolism. Xenobiotica 16:465-461
8. Heim M, Meyer UA (1991) Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP 2D6. Methods Enzymol 206:173-183
9. Sanz, EJ, Villen T, Alm C, Bertilsson L (1989) S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther 45:495-499
10. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York
11. Andersson T, Cederberg C, Regårdh C-G, Skånberg I (1990) Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 39:195-197
12. Regårdh C-G (1986) Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 21 (Suppl 118):99-104
13. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M (1993) Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45:367-371
14. Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas F (1993) Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 36:467-469
15. Gerloff J, Barth H, Mignot A, Fuchs W, Heintze K (1993) Does the proton pump inhibitor lansoprazole interact with antacids? Naunyn Schmiedebergs Arch Pharmacol 347 (Suppl):R31
16. Andersson T, Miners JO, Veronese ME, et al (1993) Identification of human liver cytochrome P-450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-530
17. Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, Van Ganse E (1992) Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 52:458-463
18. Delhotal-Landes B, Petite JP, Flouvat B (1995) Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28:458-470
19. Curi-Pedrosa R, Richard L, Bonfils C, et al (1993) Major implication of cytochrome P 450 3A4 in the oxidalive metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatozytes. Br J Clin Pharmacol 36:156P
20. Tucker GT (1994) The interaction of proton pump inhibitors with cytochromes P 450. Aliment Pharmacol Ther 8 (Suppl 1):33-38